{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T17:08:39Z","timestamp":1790960919486,"version":"4.1.0"},"reference-count":39,"publisher":"American Society of Hematology","issue":"3","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,2,10]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Natural killer (NK) large granular lymphocytic leukemia (LGLL) is a rare lymphoproliferative disorder lacking definitive clonality markers, complicating diagnosis and distinction from reactive NK cell expansions. We previously proposed an NK clonality score with high diagnostic accuracy, but a subset of patients remained unclassified. In this multicenter international study, we refined and validated updated diagnostic criteria using independent training (n = 78) and validation (n = 57) cohorts from 3 national registries (United States, Italy, and France). The revised framework integrates NK score parameters with CC motif chemokine ligand 22 (CCL22) mutations and bone marrow biopsy (BMB) findings. Four major criteria were defined: NK cell count of \u22651.0 \u00d7 109\/L, killer-cell immunoglobulin-like receptor restriction, CD94\/NKG2A overexpression, and somatic mutations in STAT3, TET2, or CCL22, the latter newly introduced. In the training cohort, 50 patients were classified as having NK-LGLL by an NK score of &amp;gt;4, 18 had intermediate scores (2-3), and 10 were diagnosed as reactive proliferations. CCL22 mutations were identified in 16 patients (20%), including 5 with intermediate scores who were reclassified as NK-LGLL; BMB supported the diagnosis in 2 additional cases, resulting in 57 NK-LGLL overall. These patients exhibited more cytopenias, higher treatment needs, and greater transfusion requirements than patients with alternative diagnoses. In the validation cohort (25 NK-LGLL and 32 reactive cases), CCL22 mutations were detected in 5 NK-LGLL (20%). Altogether, incorporation of CCL22 mutations reduced the fraction of unclassified patients, improved diagnostic sensitivity without compromising specificity, and may decrease reliance on invasive procedures. These revised international criteria represent a step toward standardized, molecularly guided NK-LGLL diagnosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025016509","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T18:02:28Z","timestamp":1762365748000},"page":"642-653","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":8,"title":["Diagnostic criteria for NK cell large granular lymphocyte leukemia: validation through a multicentric international study"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5675-3154","authenticated-orcid":false,"given":"Cedric","family":"Pastoret","sequence":"first","affiliation":[{"name":"1Laboratoire d\u2019H\u00e9matologie, P\u00f4le Biologie, Centre Hospitalier Universitaire de Rennes, Rennes, France"},{"name":"2Unit\u00e9 Mixte de Recherche UMR1236, INSERM, Universit\u00e9 Rennes, Etablissement Fran\u00e7ais du sang Bretagne, Equipe labellis\u00e9e Ligue, LabEx IGO, Rennes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Yang","sequence":"additional","affiliation":[{"name":"3Division of Hematology and Oncology, Department of Medicine, University of Virginia Cancer Center, University of Virginia School of Medicine, Charlottesville, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Feith","sequence":"additional","affiliation":[{"name":"3Division of Hematology and Oncology, Department of Medicine, University of Virginia Cancer Center, University of Virginia School of Medicine, Charlottesville, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9741-0668","authenticated-orcid":false,"given":"Mika\u00ebl","family":"Roussel","sequence":"additional","affiliation":[{"name":"1Laboratoire d\u2019H\u00e9matologie, P\u00f4le Biologie, Centre Hospitalier Universitaire de Rennes, Rennes, France"},{"name":"2Unit\u00e9 Mixte de Recherche UMR1236, INSERM, Universit\u00e9 Rennes, Etablissement Fran\u00e7ais du sang Bretagne, Equipe labellis\u00e9e Ligue, LabEx IGO, Rennes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aline","family":"Moignet","sequence":"additional","affiliation":[{"name":"4Service d\u2019H\u00e9matologie Clinique, Centre Hospitalier Universitaire de Rennes, Rennes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shubha","family":"Dighe","sequence":"additional","affiliation":[{"name":"3Division of Hematology and Oncology, Department of Medicine, University of Virginia Cancer Center, University of Virginia School of Medicine, Charlottesville, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9148-2836","authenticated-orcid":false,"given":"Micheal Dimitri","family":"Solga","sequence":"additional","affiliation":[{"name":"5University of Virginia Flow Cytometry Core Facility, University of Virginia School of Medicine, Charlottesville, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Marchand","sequence":"additional","affiliation":[{"name":"2Unit\u00e9 Mixte de Recherche UMR1236, INSERM, Universit\u00e9 Rennes, Etablissement Fran\u00e7ais du sang Bretagne, Equipe labellis\u00e9e Ligue, LabEx IGO, Rennes, France"},{"name":"4Service d\u2019H\u00e9matologie Clinique, Centre Hospitalier Universitaire de Rennes, Rennes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garance","family":"Visser","sequence":"additional","affiliation":[{"name":"1Laboratoire d\u2019H\u00e9matologie, P\u00f4le Biologie, Centre Hospitalier Universitaire de Rennes, Rennes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa Rebecca","family":"Gasparini","sequence":"additional","affiliation":[{"name":"6Hematology Section, Department of Medicine, Hematology and Clinical Immunology Branch, University of Padova, Padova, Italy"},{"name":"7Veneto Institute of Molecular Medicine, Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2754-699X","authenticated-orcid":false,"given":"Antonella","family":"Teramo","sequence":"additional","affiliation":[{"name":"6Hematology Section, Department of Medicine, Hematology and Clinical Immunology Branch, University of Padova, Padova, Italy"},{"name":"7Veneto Institute of Molecular Medicine, Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8799-5324","authenticated-orcid":false,"given":"Renato","family":"Zambello","sequence":"additional","affiliation":[{"name":"6Hematology Section, Department of Medicine, Hematology and Clinical Immunology Branch, University of Padova, Padova, Italy"},{"name":"7Veneto Institute of Molecular Medicine, Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Thomas P.","family":"Loughran","sequence":"additional","affiliation":[{"name":"3Division of Hematology and Oncology, Department of Medicine, University of Virginia Cancer Center, University of Virginia School of Medicine, Charlottesville, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Lamy","sequence":"additional","affiliation":[{"name":"2Unit\u00e9 Mixte de Recherche UMR1236, INSERM, Universit\u00e9 Rennes, Etablissement Fran\u00e7ais du sang Bretagne, Equipe labellis\u00e9e Ligue, LabEx IGO, Rennes, France"},{"name":"4Service d\u2019H\u00e9matologie Clinique, Centre Hospitalier Universitaire de Rennes, Rennes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,1,29]]},"reference":[{"issue":"9","key":"2026021015524186500_bib1","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1182\/blood-2016-08-692590","article-title":"LGL leukemia: from pathogenesis to treatment","volume":"129","author":"Lamy","year":"2017","journal-title":"Blood"},{"issue":"18","key":"2026021015524186500_bib2","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1182\/blood.2023021790","article-title":"A modern view of LGL leukemia","volume":"144","author":"Marchand","year":"2024","journal-title":"Blood"},{"issue":"2","key":"2026021015524186500_bib3","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1751-553X.2011.01374.x","article-title":"State of the art in natural killer cell malignancies","volume":"34","author":"Semenzato","year":"2012","journal-title":"Int J Lab Hematol"},{"issue":"7","key":"2026021015524186500_bib4","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"issue":"11","key":"2026021015524186500_bib5","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The International Consensus Classification of mature lymphoid neoplasms: a report from the Clinical Advisory Committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"issue":"23","key":"2026021015524186500_bib6","doi-asserted-by":"crossref","first-page":"3237","DOI":"10.1182\/blood.2020006721","article-title":"Linking the KIR phenotype with STAT3 and TET2 mutations to identify chronic lymphoproliferative disorders of NK cells","volume":"137","author":"Pastoret","year":"2021","journal-title":"Blood"},{"issue":"5","key":"2026021015524186500_bib7","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1182\/blood-2002-12-3898","article-title":"Expression and function of KIR and natural cytotoxicity receptors in NK-type lymphoproliferative diseases of granular lymphocytes","volume":"102","author":"Zambello","year":"2003","journal-title":"Blood"},{"key":"2026021015524186500_bib8","doi-asserted-by":"crossref","first-page":"106614","DOI":"10.1016\/j.leukres.2021.106614","article-title":"CD94 expression patterns in reactive and neoplastic T-cell and NK-cell proliferations","volume":"108","author":"Fang","year":"2021","journal-title":"Leuk Res"},{"issue":"40","key":"2026021015524186500_bib9","doi-asserted-by":"crossref","first-page":"42938","DOI":"10.18632\/oncotarget.5480","article-title":"Phenotypic profile of expanded NK cells in chronic lymphoproliferative disorders: a surrogate marker for NK-cell clonality","volume":"6","author":"B\u00e1rcena","year":"2015","journal-title":"Oncotarget"},{"issue":"8","key":"2026021015524186500_bib10","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1182\/blood.2020005831","article-title":"Frequent somatic TET2 mutations in chronic NK-LGL leukemia with distinct patterns of cytopenias","volume":"138","author":"Olson","year":"2021","journal-title":"Blood"},{"issue":"4","key":"2026021015524186500_bib11","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/s41408-020-0309-2","article-title":"A high definition picture of somatic mutations in chronic lymphoproliferative disorder of natural killer cells","volume":"10","author":"Gasparini","year":"2020","journal-title":"Blood Cancer J"},{"key":"2026021015524186500_bib12","doi-asserted-by":"crossref","first-page":"821382","DOI":"10.3389\/fonc.2022.821382","article-title":"Toward a better classification system for NK-LGL disorders","volume":"12","author":"Drillet","year":"2022","journal-title":"Front Oncol"},{"issue":"5","key":"2026021015524186500_bib13","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/s41588-022-01059-2","article-title":"CCL22 mutations drive natural killer cell lymphoproliferative disease by deregulating microenvironmental crosstalk","volume":"54","author":"Baer","year":"2022","journal-title":"Nat Genet"},{"issue":"9","key":"2026021015524186500_bib14","first-page":"3067","article-title":"CCL22 mutations in large granular lymphocytic leukemia","volume":"109","author":"Mizuno","year":"2024","journal-title":"Haematologica"},{"key":"2026021015524186500_bib15","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/978-3-030-36667-4_8","article-title":"CCL22 signaling in the tumor environment","volume":"1231","author":"R\u00f6hrle","year":"2020","journal-title":"Adv Exp Med Biol"},{"issue":"24","key":"2026021015524186500_bib16","doi-asserted-by":"crossref","first-page":"15638","DOI":"10.3390\/ijms232415638","article-title":"CC chemokine receptor 4 (CCR4) as a possible new target for therapy","volume":"23","author":"Bogacka","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"5","key":"2026021015524186500_bib17","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1084\/jem.20170277","article-title":"CCL22 controls immunity by promoting regulatory T cell communication with dendritic cells in lymph nodes","volume":"216","author":"Rapp","year":"2019","journal-title":"J Exp Med"},{"issue":"11","key":"2026021015524186500_bib18","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1038\/s41375-022-01695-x","article-title":"All that glitters is not LGL leukemia","volume":"36","author":"Semenzato","year":"2022","journal-title":"Leukemia"},{"issue":"20","key":"2026021015524186500_bib19","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"1","key":"2026021015524186500_bib20","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1182\/blood.V89.1.256","article-title":"The lymphoproliferative disease of granular lymphocytes: updated criteria for diagnosis","volume":"89","author":"Semenzato","year":"1997","journal-title":"Blood"},{"issue":"10","key":"2026021015524186500_bib21","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1093\/annonc\/mdu369","article-title":"Chronic natural killer lymphoproliferative disorders: characteristics of an international cohort of 70 patients","volume":"25","author":"Poullot","year":"2014","journal-title":"Ann Oncol"},{"issue":"7","key":"2026021015524186500_bib22","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/ajh.26183","article-title":"Large granular lymphocytic leukemia \u2013 a retrospective study of 319 cases","volume":"96","author":"Dong","year":"2021","journal-title":"Am J Hematol"},{"key":"2026021015524186500_bib23","doi-asserted-by":"crossref","first-page":"486","DOI":"10.3389\/fimmu.2018.00486","article-title":"CD161 defines a functionally distinct subset of pro-inflammatory natural killer cells","volume":"9","author":"Kurioka","year":"2018","journal-title":"Front Immunol"},{"key":"2026021015524186500_bib24","doi-asserted-by":"crossref","first-page":"72","DOI":"10.3389\/fimmu.2014.00072","article-title":"Activating KIRs in chronic lymphoproliferative disorder of NK cells: protection from viruses and disease induction?","volume":"5","author":"Zambello","year":"2014","journal-title":"Front Immunol"},{"issue":"15","key":"2026021015524186500_bib25","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1182\/blood-2012-06-435297","article-title":"STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia","volume":"120","author":"Jerez","year":"2012","journal-title":"Blood"},{"issue":"12","key":"2026021015524186500_bib26","doi-asserted-by":"crossref","first-page":"3508","DOI":"10.3390\/cancers12123508","article-title":"STAT3 and STAT5B mutations in T\/NK-cell chronic lymphoproliferative disorders of large granular lymphocytes (LGL): association with disease features","volume":"12","author":"Mu\u00f1oz-Garc\u00eda","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"5","key":"2026021015524186500_bib27","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s12185-019-02625-x","article-title":"STAT3 mutations in natural killer cells are associated with cytopenia in patients with chronic lymphoproliferative disorder of natural killer cells","volume":"109","author":"Kawakami","year":"2019","journal-title":"Int J Hematol"},{"issue":"3","key":"2026021015524186500_bib28","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1111\/bjh.19476","article-title":"Efficacy of ruxolitinib in the treatment of relapsed\/refractory large granular lymphocytic leukaemia","volume":"205","author":"Marchand","year":"2024","journal-title":"Br J Haematol"},{"issue":"12","key":"2026021015524186500_bib29","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1038\/leu.2015.280","article-title":"Tofacitinib as a novel salvage therapy for refractory T-cell large granular lymphocytic leukemia","volume":"29","author":"Bilori","year":"2015","journal-title":"Leukemia"},{"issue":"suppl 1","key":"2026021015524186500_bib30","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1182\/blood-2024-206053","article-title":"Results from the first phase 1 clinical study of DR-01, a non-fucosylated anti-CD94 targeting antibody in patients with relapsed\/refractory cytotoxic lymphomas: dose escalation and optimization","volume":"144","author":"Zain","year":"2024","journal-title":"Blood"},{"issue":"23","key":"2026021015524186500_bib31","doi-asserted-by":"crossref","first-page":"3156","DOI":"10.1182\/blood.2020010542","article-title":"Tracing the roots of CLPD-NK by TET2 and STAT3","volume":"137","author":"Herling","year":"2021","journal-title":"Blood"},{"issue":"6","key":"2026021015524186500_bib32","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1111\/bjh.13170","article-title":"Efficacy of 5-azacytidine in a TET2 mutated angioimmunoblastic T cell lymphoma","volume":"168","author":"Cheminant","year":"2015","journal-title":"Br J Haematol"},{"issue":"9","key":"2026021015524186500_bib33","doi-asserted-by":"crossref","first-page":"e04533","DOI":"10.1002\/ccr3.4533","article-title":"A non-cytotoxic regimen of decitabine to treat refractory T-cell large granular lymphocytic leukemia","volume":"9","author":"Zawit","year":"2021","journal-title":"Clin Case Rep"},{"issue":"12","key":"2026021015524186500_bib34","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1038\/bcj.2013.65","article-title":"Novel somatic mutations in large granular lymphocytic leukemia affecting the STAT-pathway and T-cell activation","volume":"3","author":"Andersson","year":"2013","journal-title":"Blood Cancer J"},{"issue":"12","key":"2026021015524186500_bib35","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"26","key":"2026021015524186500_bib36","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","article-title":"Clonal hematopoiesis and blood-cancer risk inferred from Blood DNA sequence","volume":"371","author":"Genovese","year":"2014","journal-title":"N Engl J Med"},{"issue":"8","key":"2026021015524186500_bib37","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1038\/s41375-018-0150-9","article-title":"Consequences of mutant TET2 on clonality and subclonal hierarchy","volume":"32","author":"Hirsch","year":"2018","journal-title":"Leukemia"},{"issue":"1","key":"2026021015524186500_bib38","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1182\/blood.V99.1.268","article-title":"Distinct bone marrow findings in T-cell granular lymphocytic leukemia revealed by paraffin section immunoperoxidase stains for CD8, TIA-1, and granzyme B","volume":"99","author":"Morice","year":"2002","journal-title":"Blood"},{"issue":"8","key":"2026021015524186500_bib39","doi-asserted-by":"crossref","first-page":"100255","DOI":"10.1016\/j.modpat.2023.100255","article-title":"Establishing NK-cell receptor restriction by flow cytometry and detecting potential NK-cell clones of uncertain significance","volume":"36","author":"Seheult","year":"2023","journal-title":"Mod Pathol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/3\/642\/2501490\/blooda_adv-2025-016509-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/3\/642\/2501490\/blooda_adv-2025-016509-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T20:52:53Z","timestamp":1770756773000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/3\/642\/548034\/Diagnostic-criteria-for-NK-cell-large-granular"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,29]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,2,10]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025016509","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2,10]]},"published":{"date-parts":[[2026,1,29]]}}}